abstract |
The present invention relates to HLA-B27Fc homodimers or HLA-B27Fc fusion protein homodimers for use in the treatment or prevention of cancer. The Fc homodimer comprises first and second monomers, or is composed of first and second monomers, and each monomer comprises HLA-B27. The Fc fusion protein homodimer further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. A further aspect of the present invention provides a combination medicament comprising the HLA-B27Fc homodimer and an immune checkpoint inhibitor. [Selection figure] None |